Compare AUBN & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | PYPD |
|---|---|---|
| Founded | 1907 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.5M | 107.0M |
| IPO Year | 1996 | 2014 |
| Metric | AUBN | PYPD |
|---|---|---|
| Price | $26.86 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 1.9K | ★ 96.0K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ 13.66 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $619,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.51 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $21.01 | $3.40 |
| 52 Week High | $28.88 | $5.73 |
| Indicator | AUBN | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 54.36 |
| Support Level | $26.02 | $4.54 |
| Resistance Level | $27.64 | $5.58 |
| Average True Range (ATR) | 0.22 | 0.24 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 53.04 | 92.06 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.